24 May 2018 - - Culver City, California-based molecular analyses company NantOmics, LLC, a member of the NantWorks ecosystem of companies, has published peer-reviewed research defining three distinct classifications of sebaceous carcinoma, a rare and sometimes deadly former of skin cancer, the company said.
Published on May 14 in the journal Nature Communications, the study shows that a signature analysis reveals three clinically distinct classes of sebaceous carcinoma.
The research offers fresh insights into how to treat the disease and adds more data to the concept that different mutational processes drive cancers that originate in the same location but are clinically distinct.
Using the technology that drives NantHealth, Inc.'s (NASDAQ: NH) GPS Cancer platform, NantOmics scientists performed tumor-normal DNA sequencing and RNA sequencing on tissue samples from 32 patients with sebaceous carcinoma, revealing that the cell of origin and mutation patterns defined three clinically distinct classes.
These explain both cancer ontogeny and clinical course.
NantOmics delivers molecular analysis capabilities with the intent of providing actionable intelligence and molecularly driven decision support for cancer patients and their providers at the point of care. The company analyzes both normal and tumor cells from the same patient, and follows identified variances through from DNA to RNA to protein to drug.
Its highly scalable cloud-based infrastructure is capable of storing and processing thousands of genomes a day, computing genomic variances in near real-time, and correlating proteomic pathway analysis with quantitative multi-plexed protein expression analysis from the same micro-dissected tumor sample used for genomic analysis.
Culver City, California-based personalized healthcare company NantHealth, Inc. (NASDAQ: NH) is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses.
The company's unique systems-based approach to personalized healthcare applies novel diagnostics tailored to the specific molecular profiles of patient tissues and integrates this molecular data in a clinical setting with large-scale, real-time biometric signal and phenotypic data to track patient outcomes and deliver precision medicine.